A Parallel Comparative Study To Evaluate The Efficacy Of Rudraksha Churna In Comparison To Jatamansyadi Kwath Churna In The Management of Stage-1 Hypertension
试验速览
- 阶段
- 2/3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- To evaluate the efficacy of Rudraksha Churna and Jatamansyadi
研究概览
简要总结
Raktagata vata can be understood by assessing the involved Doshas, Dooshyas, Srotases, Samuthan.
Sharira doshas (Vata - Pitta - Kapha) and Mansika doshas (Raja - Tama) gets vitiated by nidana sewans
which leads to Agni Mandhya, Dhatu Dushti (Rasa-Rakta) and Srotodushti (Rasavaha-Raktavaha). As a
result of this Vyana Prakopa takes place and Sthanasamsraya occurs in Dhamni, Shira and Sarwang
Sharira due to the Vikshepa bala of Vyana Vayu which leads to rise in the blood pressure. In Raktagata
vata, Rakta dhatu gets vitiated by Vata dosha, leading and it is unable to perform its normal function and
symptoms like Tivraruja, Santapa, Vaivarnya, Aruchi, Krishata Bhrama, Klama, Shirashula can be
observed in the patient. According to Acharya Charaka to understand a new clinical entity, which is not
described in the Samhita and physician is unable to diagnose the disease, then the treatment protocol
should be designed by assessing its Prakruti, Samuthan and Adhishtana
.
Cardiovascular diseases (CVDs) are the leading cause of death worldwide, and many of these deaths can
be prevented by treating hypertension. Blood pressure is created by the force of blood pushing against the
walls of blood vessels (arteries) as it is pumped by the heart. The higher the pressure, the harder the heart
must pump and the more damage this excess pressure causes to many parts of the body, especially the
brain, heart and kidneys. In about 85% -95% of cases, a specific underlying cause of hypertension cannot
be identified and such hypertension is termed as essential hypertension. To catalyze national action, the
World Health Assembly adopted a comprehensive Global Monitoring Framework in 2013, comprised of nine voluntary global targets to be reached by 2025 which included a 25% relative reduction in the
prevalence of raised blood pressure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 30.00 Year(s) 至 60.00 Year(s)(—)
- 性别
- All
入选标准
- •Patient willing for clinical trial and ready to give written Consent.
- •Patients between the age group of
- •60 years of either gender.
- •Pre-diagnosed or freshly diagnosed patient of Stage-1 Hypertension.
- •SBP 140-159mmhg, DBP 90-99mmhg (HTN stage 1).
排除标准
- •Patient having an Age below 30 and above 60 years.
- •SBP greater than 160 mmhg, DBP greater than 100 mmhg (HTN stage 2).
- •Cases linked renal, endocrine, cardiovascular diseases (Secondary Hypertension).
- •Other systemic diseases such as Diabetes, CKD etc.
- •Pregnancy and Lactation.
结局指标
主要结局
To evaluate the efficacy of Rudraksha Churna and Jatamansyadi
时间窗: 28 Days
Kwath Churna in reducing systolic and diastolic blood pressure.
时间窗: 28 Days
次要结局
- Improvement in World Health Organization Quality of life (WHOQOL Bref) Scale Score,(Improvement in Hamilton Anxiety Rating Scale Score (HAM-A).)
研究者
Dr Divya
Institute for Ayurved Studies and Reasearch kurukshetra
